中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2014年
18期
86-88
,共3页
梁丽萍%潘勇翔%陈虹%郑伟华%陈毓青%王志成%易玉芳
樑麗萍%潘勇翔%陳虹%鄭偉華%陳毓青%王誌成%易玉芳
량려평%반용상%진홍%정위화%진육청%왕지성%역옥방
慢性心力衰竭%基质金属蛋白酶-9%基质金属蛋白酶抑制剂-1%左心室射血分数%曲美他嗪
慢性心力衰竭%基質金屬蛋白酶-9%基質金屬蛋白酶抑製劑-1%左心室射血分數%麯美他嗪
만성심력쇠갈%기질금속단백매-9%기질금속단백매억제제-1%좌심실사혈분수%곡미타진
Chronic heart failure%MMP-9%TIMP-1%Left ventricular ejection fraction%Trimetazidine
目的:探讨曲美他嗪对慢性心力衰竭患者心功能和血清基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶抑制剂-1(TIMP-1)的影响.方法将2010年1月~2012年1月桂林医学院附属医院老年科80例慢性心力衰竭患者分为治疗组(41例)和对照组(39例),两组均接受血管紧张素转换酶抑制剂、β-受体阻滞剂、安体舒通、地高辛等常规治疗,治疗组在此基础上口服盐酸曲美他嗪,治疗前及治疗后6个月均测6 min步行距离、心率、MMP-9、左室射血分数(LVEF)、TIMP-1.结果治疗结束后,治疗组、对照组与治疗前比较,血清MMP-9浓度、心率降低,TIMP-1、LVEF升高(P<0.05);与对照组比较,治疗组TIMP-1、LVEF升高更明显,血清基MMP-9浓度更低(P<0.05).血清MMP-9浓度与LVEF呈负相关(r=-0.63,P<0.01);血清TIMP-1浓度与LVEF呈正相关(r=0.56,P<0.01).结论盐酸曲美他嗪可以改善慢性心力衰竭患者的心功能,同时可降低患者血清MMP-9的浓度,升高TIMP-1的浓度。
目的:探討麯美他嗪對慢性心力衰竭患者心功能和血清基質金屬蛋白酶-9(MMP-9)、基質金屬蛋白酶抑製劑-1(TIMP-1)的影響.方法將2010年1月~2012年1月桂林醫學院附屬醫院老年科80例慢性心力衰竭患者分為治療組(41例)和對照組(39例),兩組均接受血管緊張素轉換酶抑製劑、β-受體阻滯劑、安體舒通、地高辛等常規治療,治療組在此基礎上口服鹽痠麯美他嗪,治療前及治療後6箇月均測6 min步行距離、心率、MMP-9、左室射血分數(LVEF)、TIMP-1.結果治療結束後,治療組、對照組與治療前比較,血清MMP-9濃度、心率降低,TIMP-1、LVEF升高(P<0.05);與對照組比較,治療組TIMP-1、LVEF升高更明顯,血清基MMP-9濃度更低(P<0.05).血清MMP-9濃度與LVEF呈負相關(r=-0.63,P<0.01);血清TIMP-1濃度與LVEF呈正相關(r=0.56,P<0.01).結論鹽痠麯美他嗪可以改善慢性心力衰竭患者的心功能,同時可降低患者血清MMP-9的濃度,升高TIMP-1的濃度。
목적:탐토곡미타진대만성심력쇠갈환자심공능화혈청기질금속단백매-9(MMP-9)、기질금속단백매억제제-1(TIMP-1)적영향.방법장2010년1월~2012년1월계림의학원부속의원노년과80례만성심력쇠갈환자분위치료조(41례)화대조조(39례),량조균접수혈관긴장소전환매억제제、β-수체조체제、안체서통、지고신등상규치료,치료조재차기출상구복염산곡미타진,치료전급치료후6개월균측6 min보행거리、심솔、MMP-9、좌실사혈분수(LVEF)、TIMP-1.결과치료결속후,치료조、대조조여치료전비교,혈청MMP-9농도、심솔강저,TIMP-1、LVEF승고(P<0.05);여대조조비교,치료조TIMP-1、LVEF승고경명현,혈청기MMP-9농도경저(P<0.05).혈청MMP-9농도여LVEF정부상관(r=-0.63,P<0.01);혈청TIMP-1농도여LVEF정정상관(r=0.56,P<0.01).결론염산곡미타진가이개선만성심력쇠갈환자적심공능,동시가강저환자혈청MMP-9적농도,승고TIMP-1적농도。
Objective To investigate the effects of trimetazidine on cardiac function and serum level of MMP-9, TIMP-1 in patients with chronic heart failure. Methods 80 patients with chronic heart failure from January 2010 to January 2012 in Department of Geriatrics, the Affiliated Hospital of Guilin Medical College were divided into two groupstreat-ment group (41 cases) and control group (39 cases). All the patients were treated for 6 months besides conventional therapy including ACEI,β-receptor blocker, Spironolactone, Digoxin. The treatment group were given the Trimetazidine oral in addition. The heart rates, 6 min walking distance, left ventricular ejection fraction (LVEF) and serum MMP-9, TIMP-1 were evaluated before and 6 months after therapy. Results Both treatment and control group significantly in-creased the LVEF, TIMP-1, decreased the heart rates and serum MMP-9 (P<0.05), what's more, treatment group had much lower serum MMP-9 and higher LVEF, TIMP-1 than those of the control group after 6 months of treatment (r=0.56, P<0.01), moreover the MMP-9 was negative correlated with LVEF (r=-0.63, P< 0.01). TIMP-1 was positive correlated with LVEF. Conclusion Trimetazidine can improve cardiac function, TIMP-1 can decrease the serum MMP-9.